Achieving a cure for HIV infection: do we have reasons to be optimistic?

Valentin Le Douce1, Andrea Janossy1, Houda Hallay1, Sultan Ali1, Raphael Riclet1, Olivier Rohr1–3† and Christian Schwartz1,2*†

1University of Strasbourg, EA4438, Institute of Parasitology, Strasbourg, France; 2IUT de Schiltigheim, 1 Allée d’Athénes, 67300 Schiltigheim, France; 3Institut Universitaire de France, 103 Bd Saint Michel, Paris, France

*Corresponding author. Tel: +33-368853673; E-mail: schwartz.christian@unistra.fr
†These authors contributed equally.

The introduction of highly active antiretroviral therapy (HAART) in 1996 has transformed a lethal disease to a chronic pathology with a dramatic decrease in mortality and morbidity of AIDS-related symptoms in infected patients. However, HAART has not allowed the cure of HIV infection, the main obstacle to HIV eradication being the existence of quiescent reservoirs. Several other problems have been encountered with HAART (such as side effects, adherence to medication, emergence of resistance and cost of treatment), and these motivate the search for new ways to treat these patients. Recent advances hold promise for the ultimate cure of HIV infection, which is the topic of this review. Besides these new strategies aiming to eliminate the virus, efforts must be made to improve current HAART. We believe that the cure of HIV infection will not be attained in the short term and that a strategy based on purging the reservoirs has to be associated with an aggressive HAART strategy.

Keywords: CCR5, reservoirs, latency, purge, HAART

Introduction

Human immunodeficiency virus 1 (HIV-1), identified 28 years ago,1 remains a global health threat responsible for a worldwide pandemic with an estimated 33 million people infected.2 More than 7000 new HIV infections occur each day, and the number of newly diagnosed infections remains far greater than the number of people (around 50%) who have access to highly active antiretroviral therapy (HAART). Advances have been made in treating AIDS since the introduction of HAART in 1996. This has transformed a lethal disease into a chronic pathology, with a dramatic decrease of mortality and morbidity of AIDS-related symptoms in infected patients.3,4

Why is achieving a cure important?

To date, the only way to treat patients infected with HIV relies on a combination of drugs that act at different stages of the viral life cycle, preventing the virus from replicating. These molecules target four stages of the cycle: viral entry, reverse transcription of the viral genome, integration into the genome of the host cell and maturation of viral proteins. This therapy can reduce plasma virus levels below detection limits (<50 copies/mL). However, with very sensitive but expensive and technically challenging methods, a residual viraemia is still detected in patients on HAART.5–8 Moreover, HIV RNA typically returns to a measurable plasma level in less than 2 weeks when HAART is interrupted, suggesting that even long-term suppression of HIV-1 replication by HAART fails to totally eliminate HIV-1. These two latter phenomena are mainly due to the existence of HIV reservoirs.6,9–13 The existence of integrated latent viruses or virus replicating at a very low level in different cellular reservoirs is an obstacle to the eradication of the virus, and thus the total recovery of patients, and requires strict adherence to lifelong treatment.14–21 In addition, these cellular reservoirs are often found in tissue sanctuaries, such as the brain, where drug penetration may be several orders of magnitude lower than in other tissues.16,18 Viral clearance from other reservoirs, such as from chronically infected macrophages, is also difficult since reverse transcriptase inhibitors are usually ineffective and protease inhibitors have significantly lower activities in these cells than in lymphocytes.22,23 Moreover, emergence of many side effects may require the cessation of treatment.24 Furthermore, the development of many types of resistance, related to the extreme mutability of the virus and in part to treatment interruptions, has been described in the literature.25–28 Another major concern is related to non-AIDS events and non-AIDS mortality in patients having a residual viraemia and a normal CD4+ count, a situation also described in some HIV non-progressors. Owing to the residual viraemia, patients develop chronic inflammation that leads to several complications, for instance, cardiovascular disease, nephropathy, faster evolution of viral hepatitis and cancer.29–33

© The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Last but not least, a major problem related to HAART is the cost of the treatment. Even the cost associated with the cheaper generic forms of the drugs far exceeds the abilities of many resource-limited countries in providing treatment. The cost of this treatment will be increasingly important in the future, with an overall global budget requirement to address this problem from today to 2031 being estimated at US$397–727 billion. Since, to date, no effective HIV-1 vaccine is available, it appears crucial to improve HAART and to develop new strategies to cure HIV.

Which cure is needed: a functional or a sterilizing cure?

A sterilizing cure requires the total eradication of all HIV-infected cells, including quiescent reservoirs. On the other hand, a functional cure aims to mimic a situation encountered in some special patients called ‘elite controllers’ who are able to control viral replication and have less than 50 copies/mL of the virus without any treatment. Although a sterilizing cure would be the most appropriate and desirable, it may be difficult or impossible to really achieve. Only one reported case, the German case, is known in the literature that suggests a possible eradication of the virus. A functional cure appears more feasible since it seems impossible to get rid of HIV from latent cells and from sanctuaries. We have to keep in mind however that the chronic inflammation described in patients under HAART has also been described in some elite controllers who have presented with residual viremia and higher immune activation compared with healthy patients. It is very likely that these patients will develop more non-AIDS events compared with those who are uninfected or actually cured.

How might we achieve a cure?

The best scenario would be to eradicate the virus from all infected cells. Even though this appears very difficult, we should be able to drastically decrease the HIV reservoirs by identifying and then eliminating them. Residual on-going viral replication, whatever its origin, also has to be reduced to preclude non-AIDS events.

In this article we will discuss new strategies under investigation that aim to eradicate HIV from infected patients. First we will discuss a recently described case that showed a possible eradication of HIV following transplantation of CCR5-deficient haematopoietic stem cells. This strategy may open new avenues to cure HIV-infected patients. We will also discuss novel strategies based on purging reservoirs followed by aggressive HAART. This approach has already been used in several clinical trials. Finally, we believe that HAART has to be improved and/or intensified; however, we have to keep in mind that HAART alone will not allow for a cure.

The critical role of CCR5 in maintaining HIV-1 infection

A proof of concept

A report of a German patient being transplanted with stem cells from a donor who carried the Δ32 CCR5 mutation and then controlled his HIV infection has highlighted the critical role of CCR5 in maintaining HIV infection. It is well known that HIV-1 enters cells by using CD4 receptors and CCR5 or CXCR4 coreceptors and persons homozygotic for a 32 bp deletion in the gene coding for CCR5 are resistant to HIV-1 infection. It is noteworthy that the origin of the CCR5-Δ32-containing ancestral haplotype is recent (estimated range of 275–1875 years) and might be related to a historic strong selective event such as an epidemic of a pathogen that, like HIV-1, utilizes CCR5. This hypothetical epidemic has increased the frequency of this mutation in ancestral Caucasian populations. Hutter understood the significance of the CCR5 mutation and suggested that transplantation of stem cells originating from a donor homozygotic for the mutation could effectively eradicate the virus. After the relapse of leukaemia in the German patient with HIV there was no other choice but to transplant allogeneic stem cells to this person. The patient, as suggested by Hutter, received Δ32 CCR5 mutant stem cells. Following the medical intervention, the patient has stopped HAART and HIV RNA has remained below 1 copy/mL for now over 4 years. In a recent paper this group showed evidence even for a possible cure of HIV-1 infection in this patient. Indeed, they demonstrated reconstitution of both circulating and mucosal CD4 T cells that do not express CCR5 while the patient remained free of the virus. Moreover, they also found evidence that long-lived cells such as macrophages became Δ32 CCR5. Since these cells are reservoirs for the virus along with CD4 T memory cells, it appears that the size of the viral reservoir has decreased. This result was unexpected since the CD4 memory cells are still susceptible to productive infection by lymphotropic (CXCR4-tropic) HIV. The combination of radiotherapy and chemotherapy has allowed the eradication of long-lived reservoirs, which has prevented HIV rebound during the process of immune reconstitution following stem cell transplantation. Although this specific case is a real success, stem cell transplantation as a general strategy to cure infected patients is not yet feasible due to the high mortality of this treatment (20%–30%). This report constitutes a proof of concept and opens the development of new strategies targeting the CCR5 coreceptor.

CCR5 gene therapy

Among new treatments, CCR5 gene therapy could be a potential treatment to cure HIV (Figure 1). In preclinical trials, HIV-1-infected mice engrafted with zinc finger nuclease (ZFN)-modified CD4+ T cells had lower viral loads and higher CD4+ T cell counts than mice engrafted with wild-type CD4+ T cells, consistent with the potential to reconstitute immune function in individuals with HIV/AIDS by the maintenance of an HIV-resistant CD4+ T cell population. Preliminary results of two Phase 1 clinical trials using this attractive approach were presented at the 2011 Conference on Retroviruses and Opportunistic Infections (CROI). Lalezari presented data on transformed CD4+ T cells. The wild-type CD4+ T cells were obtained from six patients who had been living with HIV infection for >20 years. Participants chosen had continued low CD4+ T cell counts (ranging from 200 to 500 cells/mm³), despite receiving antiretroviral therapy, which reduced HIV viral load to an undetectable level. Both studies showed a successful and tolerated engraftment of the transformed CD4+ T cells. At the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC),
data from another clinical trial was also presented in which six subjects having initially $>450$ CD4+ T cells/mm$^3$ under HAART were followed for 12 weeks after infusion of ex vivo transformed CD4+ T cells. Only one patient in this clinical trial became undetectable for the virus. However, this patient entered the clinical study with one $\Delta 32$ CCR5 mutation. Therefore a functional cure with this gene therapy was not attained. As explained during this conference, only 5% of the total CD4+ T cells were transformed, in contrast to the 100% in the German patient who benefited from stem cell transplantation. There is hope however that this small fraction of cells will rise in the body, since it is expected that the CCR5+ cells infected by HIV-1 will die over time. It is possible that CCR5− mutants will be selected and will replace the normal CCR5+ cells, since the release of virus from these CCR5+ cells will not be able to infect the transfused population of CCR5− mutants. A much longer follow-up is needed to confirm these expectations.

The long-term control of HIV by the German patient who received a transplant of CCR5-deficient hematopoietic stem cells holds promise for a real cure, but due to its toxicity, it is not a realistic one as claimed by Lewin and Rouzioux. Further investigations in order to understand the mechanism by which HIV was eradicated have to be performed. It would also be interesting to repeat this approach in other patients, which will help us to make further conclusions. It even raises questions such as why there is no HIV rebound from long-lived viral reservoirs.

Figure 1. Promising new approaches to cure patients of HIV-1: molecular mechanisms at the macrophage level. Beside increasing the pool of new molecules and improving the currently used ones in HAART, new approaches are required to reach a full recovery from HIV-1 infection. To date, HAART can only control and prevent viral replication, but fails to achieve total viral clearance. New potential strategies include virus eradication through gene therapy and clearance of the viral reservoirs. The first strategy derived from the observation of the $\Delta 32$ CCR5 bone marrow transplanted German patient, who seems to be free of HIV-1 infection. Owing to the high risk associated with surgery and the impossibility of using this method in a large number of patients, gene therapy could be a way to disrupt the CCR5-mediated infection in order to mimic the previous results of the German patient (1). The second strategy relies on associating the current HAART with molecules activating the viral transcription and/or targeting host proteins favouring HIV-1 latency. On the one hand, the early stage of viral replication requires the transcription activator NF-$\kappa$B, thus cytokines such as TNF-$\alpha$ may allow the recovery of full viral transcription in latent reservoirs (2). On the other hand, chromatin-modifying enzymes have been associated with HIV-1 transcription extinction through fine modifications of the epigenetic code on the viral promoter. Limiting DNA methylation of the CpG islands (3), increasing activation marks, such as acetylation of histones from Nuc-1 (4), and/or avoiding marks associated with heterochromatin, such as simultaneous trimethylation of lysine 4 and lysine 9 (5,6) of histone H3 in Nuc-1 may revert the latently infected state back to productively infected macrophages. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
producing CXCR4-tropic viruses or what the role is of the transplant procedure itself in the eradication of the virus. The debate, regarding whether the treatment of the German patient represents a sterilizing cure or not, is far from over.\textsuperscript{57} Gene therapy (including CCR5 gene therapy) is indeed a very attractive approach to cure HIV-1 infection, but it is not for immediate use, even though considerable progress in gene delivery has been made.\textsuperscript{58,59} Moreover, the debate as to whether or not this gene therapy will lead to a sterilizing cure is still open.\textsuperscript{60}

Purging viral reservoirs

The main drawback of HAART is that it is unable to purge the virus from quiescent reservoirs, i.e. truly latent cells,\textsuperscript{61–63} and/or from cells with cryptic on-going HIV replication,\textsuperscript{7,64,65} or from sanctuaries such as the brain.\textsuperscript{66–68} Resting memory CD4+ T cells are the major cellular and the best characterized reservoirs in the natural host.\textsuperscript{67,69–71} The presence of latent pro-viral HIV-1 DNA in this cell population has definitely been proven.\textsuperscript{69}

Other reservoirs than resting CD4+ T cells have also been proposed.\textsuperscript{16,18–20} Genetic studies showed that during rebound viraemia (due to HAART interruption) the virus could be detected from reservoirs other than CD4+ T cells.\textsuperscript{52,72,73} It has been proposed that peripheral blood monocytes, dendritic cells and macrophages in the lymph nodes and haematopoietic stem cells in the bone marrow can be infected latently and therefore contribute to viral persistence.\textsuperscript{74–17,19,61,74} It is still debated whether or not viral persistence in these latter reservoirs is due to true latency or to a low-level on-going replication.\textsuperscript{75,76}

Deciphering the molecular mechanisms underlying HIV persistence is a prerequisite to devise novel treatments aiming to purge these reservoirs. Several recent reviews describe in more detail the mechanisms of HIV persistence with implications for the development of new therapeutic strategies.\textsuperscript{18,20,40,77–79}

Before using strategies that aim at purging the reservoir in combination with an intensified HAART, we need: (i) to identify and characterize the molecular actors involved in the persistence of latency, which relies on the chromatin environment; and (ii) to understand the mechanisms of reactivation in order to prevent it.

Persistence of latency

Once HIV-1 DNA has integrated into the host genome, and latency has been established, maintenance of HIV-1 latency depends on the chromatin environment. The chromatin organization of the HIV-1 promoter with precisely positioned nucleosomes\textsuperscript{80,81} has been well described. Nuc-1, a nucleosome located immediately downstream of the transcription initiation site, impedes long terminal repeat (LTR) activity. Epigenetic modifications and disruption of Nuc-1 are a prerequisite of activation of LTR-driven transcription and viral expression.\textsuperscript{82} It was recently found that recruitment of deacetylases and methylases on the LTR was associated with epigenetic modifications (deacetylation of H3K9 followed by H3K9 trimethylation and recruitment of HP1 proteins) in CD4+ T cells. In these experiments, the methylase Suv39H1 and the HP1γ proteins were knocked down by small interfering RNA (siRNA). The depletion of these factors increased the level of HIV-1 expression.\textsuperscript{83}

Epigenetic modifications of the LTR have also been described in microglial cells, the CNS-resident macrophages. These cells are major targets for HIV-1 and constitute latently infected cellular reservoirs in the brain.\textsuperscript{84} Previous work from our laboratory has shown that a COUP-TF interacting protein 2 (CTIP2), a recently cloned transcriptional repressor that can associate with members of the COUP-TF family,\textsuperscript{35} inhibits HIV-1 replication in human microglial cells.\textsuperscript{85,87} Subsequently we showed that CTIP2 inhibited HIV-1 gene transcription in these cells by recruiting a chromatin-modifying complex.\textsuperscript{88} As demonstrated in T lymphocytes, our work suggests a concomitant recruitment of histone deacetylases HDAC1, HDAC2 and methylase SUV39H1 to the viral promoter by CTIP2. Ordered histone modifications would allow HP1 binding, heterochromatin formation and, as a consequence, HIV silencing. The heterochromatin formation at the HIV-1 promoter has been linked to post-integration latency and, this suggests that transcriptional repressors such as CTIP2 are involved in the establishment and maintenance of viral persistence and post-integration latency in the brain.

The corepressor CTIP2 has an even more pleiotropic action by regulating the expression of genes of infected cells. Recruited to the cellular cyclin-dependent kinase inhibitor CDKN1A/p21\textsuperscript{waf1} (p21) promoter, CTIP2 silences p21 gene transcription by inducing epigenetic modifications, as described above, for the HIV-1 promoter. This effect indirectly favours HIV-1 latency since activation of the p21 gene stimulates viral expression in macrophages.\textsuperscript{89} Moreover, CTIP2 counteracts HIV-1 Vpr, which is required for p21 expression. We suggest that all these factors contribute together to HIV-1 transcriptional latency in microglial cells.\textsuperscript{90} The picture regarding the importance of p21 in the replicative cycle of HIV-1 is far more complicated since p21 has been described as a restriction factor in macrophages and in resting CD4 T cells.\textsuperscript{91,92} The protein p21 might have different effects on HIV-1 infection of macrophages depending on the targeted viral life cycle step, and therefore on the time since infection.\textsuperscript{93}

We have also identified a new actor involved in the maintenance of HIV-1 latency in microglial cells, the lysine-specific demethylase (LSD1).\textsuperscript{94} We notably showed that LSD1 repressed HIV-1 transcription and viral expression in a synergistic manner with CTIP2 and reported that recruitment of LSD1 at the HIV-1 proximal promoter is associated with both H3K4me3 and H3K9me3 epigenetic marks. Association of both H3K4me3 and H3K9me3 epigenetic marks with LSD1 recruitment may thus constitute a new level of eukaryotic gene regulation. These observations are consistent with the discovery that H3K4 methylation at certain chromatin loci may prevent gene expression.\textsuperscript{95} Interestingly, such a gene repression linked to H3K4me3 has been proposed to prevent the expression of cryptic promoters.\textsuperscript{95,96} This is strengthened by the finding that HIV-1 preferentially integrates into active genes and therefore could be considered as a cryptic gene.

Surprisingly, LSD1 has been associated with activation of HIV transcription in CD4+ T cells through demethylation of K55 K5.\textsuperscript{97} However, in microglial cells the mechanisms underlying LSD1-mediated increase of H3K4 trimethylation is different and might rely on the ability of LSD1 to anchor other factors at the promoter rather than its own enzymatic activity. Indeed, H3K4 trimethylation was associated with the recruitment of LSD1, hSET1 and WDR5 at the Sp1 binding sites of the HIV-1 LTR. Moreover, reactivation of HIV-1 proviruses correlated with the release
of LSD1, hSET1 and WDR5 from the viral promoter and with a reduced H3K4 trimethylation. In contrast to CD4+ T cells, LSD1 is involved in the maintenance of HIV-1 latency in microglial cells by favouring a local heterochromatin structure. These two studies reporting a dual role of LSD1 through different mechanisms in two main HIV-1 targets point to the complexity of HIV latency and raise the question of how effective the use of inhibitors of LSD1 would be for full HIV-1 reactivation. Indeed, targeting LSD1 for full reactivation in microglial cells might not work in lymphocytes. Instead, in the latter cells an induction of HIV latency is expected.98 Further investigation of the epigenetic regulation of HIV latency is therefore needed in order to design efficient drugs targeting viral reservoirs.

Another field of interest is DNA methylation, which has been involved in DNA silencing and latency.99 It is now well established that DNA CpG methylation plays an important role in maintaining HIV-1 latency,100,101 despite previous controversies.102 Therefore DNA methylase inhibitors, such as 5-azacytidine, could be useful in strategies aiming to reactivate reservoirs. It is noteworthy that only a few percent of the latent viruses are methylated on their DNA, but these reservoirs of latent viruses are highly resistant to reactivation. Achieving a cure would probably require the treatment of many different types of latency simultaneously by a combination therapy approach.

Preventing reactivation

Several mechanisms acting at the transcriptional and post-transcriptional level are at work in order to preclude HIV reactivation in latent reservoirs. Affecting these mechanisms may open new ways to purge reservoirs. Sequestration of nuclear factor κB (NF-κB) in the cytoplasm of latent cells is one of these mechanisms.103 T cell activation with tumour necrosis factor alpha (TNF-α) allows translocation to the nucleus of NF-κB, which then binds to the LTR and activates the early phase (Tat independent) virus transcription (Figure 1). Besides TNF-α, many other factors have been involved in HIV reactivation, including interleukins (IL) IL-1β, IL-2, IL-6, IL-7, interferon γ (IFN-γ) and CD154,104–109 and could be used to purge the reservoirs. Among mechanisms acting at the post-transcriptional level, regulation of the exportation of viral RNAs by the poly track binding protein (PTB) seems to be important in memory CD4+ T cells.110 Another important mechanism that acts at the post-transcriptional level involves microRNAs (miRNAs). These are single-stranded RNAs of 19–25 nucleotides involved in various biological processes in eukaryotic cells.111,112 miRNAs interact with a complementary sequence in the 3′-untranscribed region (UTR) of target mRNAs by partial sequence matching, which leads either to mRNA degradation or, more often, to translational inhibition.113 miRNAs are involved in the regulation of virus expression as well.113 Recently it was shown that miRNAs regulate the expression of the histone acetyltransferase Tat cofactor PCAF and HIV replication.114 In a recent paper, Huang et al. reported an enrichment of miRNAs in clusters, which has been observed only in resting CD4+ T cells and not in active CD4+ T cells.115 They found that several of the miRNA clusters inhibited HIV replication, and suggested that miRNAs contribute to HIV latency in resting primary CD4+ T cells. They proposed to use specific antagonists (anti-miRNA antisense) raised against these miRNA in order to reactivate latent CD4+ T cells.116 However, as discussed by Sun and Rossi, the use of antagonirs to reactivate latently infected cells could be toxic for uninfected cells.117 The feasibility of using miRNAs for HIV treatment is premature and will need for more investigation.

Implications for therapies based on purging reservoirs

Original strategies based on the combination of a purge of the reservoirs and intensifying HAART aim to eradicate the virus from infected patients. Understanding the molecular mechanisms involved in latency will allow us to devise new strategies that will facilitate the reactivation of all the reservoirs.

One strategy, known as ‘Immune Activation Therapy’, aims to activate T cells118–121 (Figure 1). Many physiological stimuli that effectively activated T cells passed preclinical studies, but all failed in clinical studies.122 IL-7 held promise since this cytokine is known to be essential for the maintenance of T cell homeostasis. Indeed, there are two subsets of memory T cells:10 central memory T cells (Tcm), which are maintained through T cell survival and low-level driven proliferation and can persist for decades, and transitional memory T cells (Ttm), which persist, in contrast, by homeostatic proliferation of infected cells and could be reduced by using drugs preventing memory T cells from dividing. Interestingly, an IL-7-driven proliferation of Ttm cells can induce HIV expression from quiescent resting cells without the death of the infected cells. This cytokine might therefore be tested for its ability to reactivate expression of latent HIV in order to purge this quiescent HIV reservoir.123–125 A clinical trial using IL-7 in order to reduce the size of the latent reservoir is currently running (ERAMUNE led by C. Katlama; http://www.clinicaltrials.gov). Another profound therapeutic implication, put forward by Chomont et al.,126 is that the size of the pool of CD4+ Tcm cells infected by HIV-1 should decrease with early treatment interventions.126 Indeed, these memory Tcm cells (and the CD8+ T cells) are thought to be very important in the control of HIV infection, as shown in elite controllers.127,128 Since IL-7 is also involved in CD4+ T cell function and T cell survival,129–131 an early treatment that combines HAART and IL-7 will certainly help patients to control their HIV-1 infection (i.e. to get a functional cure), but might not allow the eradication of the virus (i.e. to get a sterilizing cure).

A second strategy aiming to develop rational therapeutics to flush out HIV from latency relies on the knowledge of its epigenetic regulation.132 (Figure 1). Several potential interesting candidates have emerged, such as the histone deacetylase (HDAC),8 anisomycin,59 the histone methyltransferase, 83,88,133 DNA methyltransferases (DNMTs),100,101 and proteins from the SWI/SNF chromatin complexes.134,135 A switch from latent to active transcription has been described following treatment with several HDAC inhibitors such as trichostatin, trapoxin, valproic acid and sodium butyrate.136–141 Valproic acid has been described to effectively reactivate latent HIV reservoirs in a first clinical trial,142,143 but two other clinical trials did not confirm this.144,145 Failure of this first clinical trial might be due to the ineffectiveness of valproic acid in inhibiting HDAC3 activity in CD4+ T cells.146 Indeed, several other HDACs, including HDAC3, contribute to the repression of HIV-1 LTR expression.147–149 Further investigations are needed using inhibitors against newly identified epigenetic regulators of HIV latency such as chaetocine (a histone methyl transferase inhibitor) or the DNA
methytransferase inhibitors, including well-characterized nucleotide analogue methylation inhibitors (5-azacytidine, 5-aza-2-deoxycytidine, 5-fluoro-2-deoxycytidine and zebularidine) and non-nucleoside DNA methylation inhibitors (procaine, procainamide, hydralazine and RG108). Purging of latent reservoirs could also be achieved by inhibiting regulatory processes that prevent reactivation. The p-TEFb activator HMBA is a promising molecule currently under study. In pilot studies it was able to reactivate latent infected cells and prevent re-infection by down-regulating CD4 receptor expression.

There are several encouraging new directions in the purging of reservoirs that are based on a combination therapy approach, as already used in clinical trials to treat cancer. Such an approach has been found to be promising since the association of an HDAC inhibitor or a DNA methylation inhibitor with prostratin has a synergistic effect on the activation of HIV-1 expression. The main benefit of this synergistic effect is that we might use drugs at suboptimal concentrations that would be sufficient to reactivate the virus but would have fewer side effects. We believe that the most promising strategy to purge the reservoir relies on combinations of such drugs, which would be able to force viral gene expression at both the transcriptional and post-transcriptional levels.

Finally, an alternative option has been proposed, which is not based on virus reactivation, but on rendering the virus unable to replicate in latent cells without inducing cell death. This original ‘genome editing therapy’ is based on the recognition of essential sequences within HIV-1, such as the pal gene by zinc finger endonuclease. Such a therapy has already been proposed to disrupt the CCR5 gene, as described previously.

**Improving HAART**

**Why is it important to improve HAART?**

There are several reasons why HAART should be improved. One is the existence of a residual viraemia in patients undergoing HAART. The origin of this viraemia is still debated. There are two theories explaining this residual viraemia: (i) long-lived cells containing latent HIV provirus that can produce HIV at low levels following reactivation; and (ii) low-level cryptic on-going replication despite therapy. Latency is best described as a lack of proviral gene expression. In contrast, on-going replication requires continuous viral gene expression without cytotoxic effects. Ineffective treatment in cells supporting on-going replication could result from poor drug penetration into sanctuaries such as the brain, where infected microglial cells are located, or from cell-to-cell transfer of the virus. It is important to distinguish between these two theories, since the therapeutic approaches they suggest are essentially different. The theory of on-going replication suggests that drug resistance to treatments might develop. In this case treatment intensification and the design of new anti-HIV-1 molecules are needed in the long term. On the other hand, if viruses are released in bursts from stable reservoirs, multidrug resistance does not develop, however, HAART alone is ineffective as well. Several studies have looked at the efficiency of such intensification of HAART on residual viraemia and only one failed to reduce it. The second reason to improve HAART is related to the ‘shock and kill’ strategy discussed above. HAART by itself is not able to achieve a cure, but is still needed (to kill) in association with HIV reactivation from quiescent cells (to shock). Finally, emergence of drug resistances, toxicity and compliance with treatment are all obstacles to the current management of HIV-1 infection and therefore need improvement of HAART.

**How can we improve HAART?**

Current management of HIV-1 treatment is based on seven classes of antiretrovirals: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), entry/fusion inhibitors (EIs), coreceptor inhibitors (CRIs) and integrase inhibitors (INs). The therapy of HIV-1-infected patients is based on a combination of three or more drugs from two or more classes.

We believe that new drugs should target other steps of the HIV-1 cycle such as transcription, since there is no drug currently available targeting this step. An increasing number of studies suggest that inhibitors of cellular LTR-binding factors, such as NF-kB and Sp1, repress LTR-driven transcription. Recently it has been shown that proteins of the DING family are good candidates to repress HIV-1 gene transcription. Indeed, the inhibitory effect of the human DING protein named HPBP (human phosphate binding protein) on HIV-1 replication is very strong, even compared with other canonical drugs currently used in HAART. HPBP is also a potent anti-HIV-1 drug in peripheral blood lymphocytes and in primary macrophages, which is not true for several other anti-HIV-1 drugs. Very interestingly, HPBP, which targets transcription, is as effective against drug-resistant HIV strains as wild-type strains, highlighting the potential therapeutic advantage of HPBP. Moreover, such drugs could also be used to cope with chronic inflammation, which leads to non-AIDS events. We believe that this protein or its derivatives are potentially interesting molecules and deserve further study. As suggested for X-DING-CD4, proteins belonging to the DING protein family might have a role in the innate response to infections, including HIV-1.

Finally, the use of nanotechnology involving structures 1–100 nm in size is an exciting approach since it will make it possible to reduce toxicity and facilitate treatment adherence. Indeed, these nano-delivery systems will permit: (i) modulation of drug release; (ii) protection of drugs from metabolism; and (iii) specific targeting of infected cells, even those located in sanctuaries. In corollary, this approach will allow improved bioavailability and therefore reduce toxicity. Among new nanotechnology-based drug delivery systems are liposomes, polymeric micelles, dendrimers and nanosuspensions. Potential uses of these molecules have been reviewed. This elegant approach will surely improve gene therapy, immunotherapy, vaccinology and microbicides.

**When to start antiretroviral therapy?**

Today there is no real consensus on when HAART should be started. Until now, generally HAART was started when the CD4+ T cell count was below 350 cells/mm³, however, several observations have pointed to a substantial benefit in reduced mortality if treatment is started at an earlier stage with no consideration of CD4+ T cell count. This is in agreement with
the finding that starting treatment earlier reduced the size of the latently infected reservoirs, as discussed above. Another major concern with starting treatment earlier is that it should reduce the outcome of non-AIDS events and non-AIDS mortality. \(^ {183}\) The cost of the treatment, drug toxicities and non-adherence to the treatment by healthy patients has led some regulatory organizations in Europe not to recommend initiation of HAART in asymptomatic patients or patients having more than 350 CD4+ T cells/mm\(^3\).

Conclusions

Are there reasons to be optimistic that a cure for HIV infection may be achieved? From our point of view the answer is ‘yes’, but this will not be achieved in the short term. Advances in some fields are very exciting and offer new opportunities to achieve a cure. For example, using gene therapy to confer HIV resistance (including the CCR5 gene therapy) is a valuable approach compared with chemotherapy, which has several drawbacks, including toxicities, development of resistance and cost. Several gene therapy trials are currently under way, \(^ {58}\) but it is premature to make definitive conclusions regarding the feasibility of these therapies. The ‘holy grail’ for clinicians will be to achieve a sterilizing cure with total eradication of the virus from the body, but we might only get a functional cure, with few patients who control HIV-1 infection (the elite controllers). The major concern with a functional cure will be to drastically reduce the viraemia in order to prevent non-AIDS events. The ‘shock and kill’ strategy has also emerged as an exciting potential way to eliminate the virus. Here, too, we might be able to achieve only a functional cure. The German case is the only case where a possible sterilizing cure has occurred, incidentally indicating a weakness of HIV. Today, however, we are limited by a lack of technology to clearly demonstrate that this patient is definitively cured. The war against this virus is far from over and will need much more work. This review has focused on current therapeutic strategies that could lead in the long term to a cure. From a military point of view, this latter strategy constitutes the first front line. However, to win a war you usually need to open a second front line, and this one is research leading to the development of an HIV vaccine. Even if in practice this approach is not yet working, efforts in this direction must be made, but might require new avenues in HIV immunology research. \(^ {36,184–186}\) Undoubtedly research aiming at a therapeutic cure will benefit from research aiming to develop a vaccine, and vice versa. Reasons to be optimistic come mainly from the intensive efforts made in different fields of research, i.e. a multidisciplinary approach, including immunologists, virologists, molecular biologists, clinicians, pharmacologists, chemists, physicists and mathematicians, who have already opened new ways and elaborated new concepts for therapies that are currently being tested in clinical trials.

Funding

This work was supported by grants from the Agence Nationale de Recherches sur le SIDA (ANRS) (to O. R., C. S. and R. R.), Sidaction Ligue contre le cancer (to O. R. and C. S.) and Institut Universitaire de France (to O. R.). A. J. is a fellow supported by the “Région Alsace”. V. L. D. is supported by a doctoral grant from the French Ministry of Research. S. A. is supported by a doctoral grant from the Pakistan Ministry of Research.

Transparency declarations

None to declare.

References

1 Barre-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868–71.
2 UN/WHO. AIDS epidemic update 2010. http://wwwunaids.org/en/ (01 December 2011, date last accessed).
3 Guilk RM, Mellors JW, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734–9.
4 Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725–33.
5 Chun TW, Stuyver L, Mizell SB et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94: 13193–7.
6 Finzi D, Hermankova M, Pierson T et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295–300.
7 Wong JK, Hezareh M, Gunthard HF et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291–2.
8 Palmer S, Maldarelli F, Wiegand A et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008; 105: 3879–84.
9 Carter CC, Onafuwo-Nuga A, McNamara LA et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 2010; 16: 446–51.
10 Chomont N, El-Far M, Ancuta P et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15: 893–900.
11 Dai J, Agosto LM, Baytop C et al. Human immunodeficiency virus integrates directly into naive resting CD4+ T cells but enters naive cells less efficiently than memory cells. J Virol 2009; 83: 4528–37.
12 Ellory PJ, Tippett E, Chiu YL et al. The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol 2007; 178: 6581–9.
13 Wightman F, Solomon A, Khoury G et al. Both CD31(+) and CD31 naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis 2010; 202: 1738–48.
14 Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res 2008; 6: 388–400.
15 Alexaki A, Wigdahl B. HIV-1 infection of bone marrow hematopoietic progenitor cells and their role in trafficking and viral dissemination. PLoS Pathog 2008; 4: e1000215.
16 Coleman CM, Wu L. HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology 2009; 6: 51.
17 Keele BF, Tazi L, Gartner S et al. Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J Virol 2008; 82: 5548–61.
HIV-1 latency provides clues for the eradication of long-term reservoirs. Coiras M, Lopez-Huertas MR, Perez-Olmeda M. Clin Immunol 2008; 77: 68–73.

Deeks SG, McCune JM. Can HIV be cured with stem cell therapy? Nat Biotechnol 2010; 28: 807–10.

Bailey JR, Sedaghat AR, Kieffer T et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 2006; 80: 6441–57.

Chun TW, Davey RT Jr, Ostrowski M et al. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med 2000; 6: 757–61.

Nickle DC, Jensen MA, Shriver D et al. Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartments. J Virol 2003; 77: 5540–6.

Dornadula G, Zhang H, VanUitert B et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999; 282: 1627–32.

Palmer S, Wiegard AP, Maldarelli F et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41: 4531–6.

McGee B, Smith N, Awee L F. HIV pharmacology: barriers to the eradication of HIV from the CNS. HIV Clin Trials 2006; 7: 142–53.

Sowchuk RJ, Yang Z. Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. Adv Drug Deliv Rev 1999; 39: 5–31.

Solas C, Lafaëulade A, Halfon P et al. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47: 238–43.

Chun TW, Carruth L, Finzi D et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387: 183–8.

Chun TW, Finzi D, Margolick J et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995; 1: 1284–90.

Perlson AS, Essunger P, Cao Y et al. Genetic characterization of HIV-1-infected compartments during combination therapy. Nature 1997; 387: 188–91.

Ho DD, Zhang L. HIV-1 rebound after anti-retroviral therapy. Nat Med 2000; 6: 736–7.

Dybul M, Daucher M, Jensen MA et al. Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy. J Virol 2003; 77: 3229–37.

McNamara LA, Collins KL. Hematopoietic stem/precursor cells as HIV reservoirs. Curr Opin HIV AIDS 2011; 6: 43–8.

Crowe S, Zhu T, Muller WA. The contribution of monocyte infection and trafficking to viral persistance, and maintenance of the viral reservoir in HIV infection. J Leukoc Biol 2003; 74: 635–41.

Shen L, Siliciano RF. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 2008; 122: 22–8.

Coiras M, Lopez-Huertas MR, Perez-Olmeda M et al. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol 2009; 7: 798–812.

Colin L, Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 2009; 6: 111.

Margolis DM. Mechanisms of HIV latency: an emerging picture of complexity. Curr HIV/AIDS Rep 2010; 7: 37–43.

Van Lint C, Emiliani S, Ott M et al. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 1996; 15: 1112–20.

Verdin E, Paras P Jr, Van Lint C. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 1993; 12: 3249–59.

Van Lint C. Role of chromatin in HIV-1 transcriptional regulation. Adv Pharmacol 2000; 48: 121–60.

du Chene I, Basyuk E, Lin Y L et al. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J 2007; 26: 424–35.

Barber SA, Gama L, Dudaronek JM et al. Mechanism for the establishment of transcriptional HIV latency in the brain in a simian immunodeficiency virus-macaque model. J Infect Dis 2006; 193: 963–70.

Avram D, Fields A, Pretty On Top K et al. Isolation of a novel family of C(2)H(2) zinc finger proteins implicated in transcriptional repression mediated by chicken ovalbumin upstream promoter transcription factor (COPF-TF) orphan nuclear receptors. J Biol Chem 2000; 275: 10315–22.

Marban C, Redel L, Suzanne S et al. COUP-TF interacting protein 2 represses the initial phase of HIV-1 gene transcription in human microglial cells. Nucleic Acids Res 2005; 33: 2318–31.

Rohr O, Lecestre D, Chasserot-Golaz S et al. Recruitment of Tat to heterochromatin protein HP1 via interaction with CTIP2 inhibits human immunodeficiency virus type 1 replication in microglial cells. J Virol 2003; 77: 5415–27.

Marban C, Suzanne S, Dequiedt F et al. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J 2006; 25: 412–23.

Vazquez N, Greenwell-Wild T, Marinos NJ et al. Human immunodeficiency virus type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulation. J Virol 2005; 79: 4479–91.

Chevrier T, Suzanne S, Redel L et al. p21(WAF1) gene promoter is epigenetically silenced by CTIP2 and SUV39H1. Oncogene 2009; 28: 3380–9.

Bergamaschi A, David A, Le Rouzic E et al. The CDK inhibitor p21(Cip1/WAF1) is induced by C(2)H(2) zinc finger proteins implicated in transcriptional repression mediated by chicken ovalbumin upstream promoter transcription factor (COPF-TF) orphan nuclear receptors. J Biol Chem 2006; 281: 12253–65.

Chen H, Li C, Huang J et al. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest 2011; 121: 1549–60.

Bergamaschi A, Pancino G. Host hindrance to HIV-1 replication in monocytes and macrophages. Retrovirology 2010; 7: 31.

Le Douce V, Colin L, Redel L et al. LSD1 cooperates with CTIP2 to promote HIV-1 transcriptional silencing. Nucleic Acids Res 2011.

Pinskaya M, Gouvennec S, Marillon A. H3 lysine 4 di- and tri-methylation deposited by cryptic transcription attenuates promoter activation. EMBO J 2009; 28: 1697–707.

Pinskaya M, Marillon A. Histone H3 lysine 4 di-methylation: a novel mark for transcriptional fidelity? Epigenetics 2009; 4: 302–6.

Sakane N, Kwon HS, Pagans S et al. Activation of HIV transcription by the viral Tat protein requires a demethylation step mediated by...
lysin-specific demethylase 1 (LSD1/KDM1). PLoS Pathog 2011; 7: e1002184.

98 Ott M, Geyer M, Zhou Q. The control of HIV transcription: keeping RNA polymerase II on track. Cell Host Microbe 2011; 10: 426 – 35.

99 Pierard V, Guiquen A, Coïn L et al. DNA cytosine methylation in the bovine leukemia virus promoter is associated with latency in a lymphoma-derived B-cell line: potential involvement of direct inhibition of cAMP-responsive element (CRE)-binding protein/CRE modulator/activation transcription factor binding. J Biol Chem 2010; 285: 19434 – 49.

100 Blazkova J, Trejbalova K, Gondois-Rey F et al. CpG methylation controls reactivation of HIV from latency. PLoS Pathog 2009; 5: e1000554.

101 Kauder SE, Bosque A, Lindqvist A et al. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 2009; 5: e1000495.

102 Plon M, Jordan A, Biancotto A et al. Transcriptional suppression of in vitro-integrated human immunodeficiency virus type 1 does not correlate with proviral DNA methylation. J Virol 2003; 77: 4025 – 32.

103 Ganesh L, Burstein E, Guho-Niyogi A et al. The gene product Mrn1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature 2003; 426: 853 – 7.

104 Biswas P, Poli G, Kinter AL et al. Interferon gamma induces the expression of immunodeficiency virus in persistently infected promonocytes (U1) and redirects the production of virions to intracytoplasmic vacuoles in phorbol myristate acetate-differentiated U1 cells. J Exp Med 1992; 176: 739 – 50.

105 Butera ST, Perez VL, Wu BY et al. Oscillation of the human immunodeficiency virus surface receptor is regulated by the state of viral activation in a CD4+ cell model of chronic infection. J Virol 1991; 65: 4645 – 53.

106 Duh EJ, Maury WJ, Folks TM et al. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of a novel factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci USA 1998; 86: 5974 – 8.

107 Folks TM, Justement J, Kinter A et al. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 1987; 238: 800 – 2.

108 Folks TM, Justement J, Kinter A et al. Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J Immunol 1988; 140: 1117 – 22.

109 Poli G, Kinter AL, Faucci AS. Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist. Proc Natl Acad Sci USA 1994; 91: 108 – 12.

110 Lassen KG, Ramyar KX, Bailey JR et al. Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog 2006; 2: e68.

111 Ambros V, Chen X. The regulation of genes and genomes by small RNAs. Development 2007; 134: 1635 – 41.

112 Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281 – 97.

113 Yeung ML, Benkirane M, Jeang KT. Small non-coding RNAs, mammalian cells, and viruses: regulatory interactions? Retrovirology 2007; 4: 74.

114 Triboulet R, Mari B, Lin YL et al. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science 2007; 315: 1579 – 82.

115 Huang J, Wang F, Argyris E et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med 2007; 13: 1241 – 7.

116 Zhang H. Reversal of HIV-1 latency with anti-microRNA inhibitors. Int J Biochem Cell Biol 2009; 41: 451 – 4.
178 das Neves J, Amiji MM, Bahia MF et al. Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv Drug Deliv Rev 2010; 62: 458–77.

179 Sharma P, Garg S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev 2010; 62: 491–502.

180 Mamo T, Moseman EA, Kolishetti N et al. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond) 2010; 5: 269–85.

181 Kitahata MM, Gange SJ, Abraham AG et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815–26.

182 Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119–29.

183 Kitahata MM. When to start antiretroviral therapy. Top HIV Med 2010; 18: 121–6.

184 Armitage AE, McMichael AJ, Drakesmith H. Reflecting on a quarter century of HIV research. Nat Immunol 2008; 9: 823–6.

185 Johnston MI, Fauci AS. An HIV vaccine—evolving concepts. N Engl J Med 2007; 356: 2073–81.

186 Fauci AS, Johnston MI, Dieffenbach CW et al. HIV vaccine research: the way forward. Science 2008; 321: 530–2.